Galapagos Enters Three-year Collaboration with Roche
News Mar 28, 2006
Galapagos NV has announced that Galapagos' service division, BioFocus, has entered into three-year collaboration with Roche. This agreement builds on the working history between Roche and BioFocus.
Under the terms of the agreement, BioFocus will supply Roche with exclusive chemical compound libraries.
BioFocus will synthesize chemical compound libraries based on Roche's framework structures and provide these collections on an exclusive basis to Roche.
These libraries will be generated using a combination of BioFocus' molecular informatics tools and a wide range of synthetic chemistry capabilities.
BioFocus designs and synthesizes both exclusive as well as non-exclusive (SoftFocus®) chemical compound libraries that can be used in drug discovery programs, including hit finding, lead optimization and patent exemplification.
"We are very pleased with this new agreement to deliver exclusive compound libraries to complement Roche's drug discovery programs," said Onno van de Stolpe, CEO of Galapagos.
"With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE